Table 5.

Estimated additional (+) impacts of seasonal trivalent influenza vaccination extrapolated to EU-27

Influenza-related event	Numbers and costs averted additional (+) to currently averted events if VCR is increased to 75% (lower, upper limit)
	Estimates using effectiveness values		Estimates using efficacy values
	Number of events averted	Costs averted	Number of events averted	Costs averted
Cases of influenza	+1.6 million (0.85; 2.0)	-	+1.7 million (1.1; 2.1)	-
Influenza-related mortality	+9,843 (4,185; 14,831)	-	+14,342 (8,620; 17,939)	-
Influenza- related GP visits	+678,482 (424,321; 849,284)	+€20 million (13; 25)	+767,787 (543,913; 935,732)	+€23 million (16; 28)
Influenza-related hospitalization	+23,792 (11,199; 33,525)	+€ 57 million (28; 81)	+31,350 (19,545; 39,254)	+€75 million (47; 94)
Lost days of work	+883,750 (671,094; 1,081,253)	+€112 million (85; 137)	+1,015,145 (783,557; 1,184,489)	+€128 million (99;150)
All Influenza-related costs	-	+€190 million (125; 243)	-	+€226 million (162;272)